Razelle Kurzrock: Outstanding work from our precision immunotherapy team and collaborators

Razelle Kurzrock shared a post by Yuji Uehara, Medical Oncologist at National Cancer Center Hospital East, Komagome Hospital, on X, adding:

“Outstanding work from Dr Uehara and our precision immunotherapy team and collaborators.”

Quoting Yuji Uehara’s post:

“HOT off the press for cancer communications with our Razelle Kurzrock:

・4-1BB and its ligand vary in exp. within and between tumor types → suboptimal outcomes in current 4-1BB targeting trials
・Individual immune profiling is needed for personalized immunotherapy.”

4-1BB transcriptomic expression patterns across malignancies: Implications for clinical trials of 4-1BB agonists

Autors: Yuji Uehara, Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary K. Nesline, Sarabjot Pabla, Jeffrey M. Conroy, Paul DePietro, Heidi Ko, Jason K. Sicklick, Razelle Kurzrock

Source: Razelle Kurzrock/X and Yuji Uehara/X

Dr. Razelle Kurzrock is the Chief Medical Officer at ACT Genomics, Senior Deputy Director at the HKSH Cancer Centre, and Senior Advisor at CureScience.

She is also a Professor of Medicine at the University of California, San Diego (UCSD) and the Director of the Center for Personalized Cancer Therapy at UCSD.

Additionally, Dr. Kurzrock is the founding director of the Michels Rare Cancers Research Laboratories at the MCW Cancer Center.